Thiotepa
Thiotepa 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Acute Leukemia、Acute Lymphoblastic Leukemia、Acute Myeloid Leukemia、Myelodysplastic Syndrome。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
1 项
已进入 III/IV 期
7 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Fred Hutchinson Cancer Center
- Masonic Cancer Center, University of Minnesota
- University of Wisconsin, Madison
- The First Affiliated Hospital with Nanjing Medical University
- Paul Szabolcs
- Peking University People's Hospital
- Children's Hospital of Philadelphia
- M.D. Anderson Cancer Center
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、中国、法国、加拿大、Russia、澳大利亚、新西兰
正在招募患者的 Thiotepa 研究
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
II 期招募中美国NCT02605421Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
I 期招募中美国NCT02508038The Study of the Combination of Thiotepa and Pomalidomide for the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma Patients.
II 期招募中中国NCT05931328Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders
II 期招募中美国NCT03980769Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
II 期招募中美国NCT01962415Thiotepa-Containing Conditioning Regimen for Allogeneic HSCT in Chronic Myelomonocytic Leukemia
不适用招募中中国NCT07588594CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT
不适用招募中美国NCT03810196Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
II 期 / III 期招募中美国NCT04708054TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies
I 期招募中美国NCT07052370Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
II 期招募中美国NCT03970096Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure
I 期 / II 期招募中美国NCT03500731Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation
II 期招募中美国NCT06807606CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
I 期招募中美国NCT07257419Thiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma
II 期招募中中国NCT07416890Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation
II 期招募中法国NCT06252870Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)
I 期招募中美国NCT06193759Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation
早期 I 期招募中加拿大NCT06942039Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies
I 期招募中美国NCT07565220The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
II 期招募中美国NCT03509961Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
II 期招募中美国NCT03630211Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML
I 期 / II 期招募中美国NCT06158828PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of Immunity
II 期招募中RussiaNCT06199427A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
II 期招募中美国澳大利亚加拿大新西兰NCT04684368Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvement
不适用招募中中国NCT06111612
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。